129 related articles for article (PubMed ID: 24276948)
1. Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters.
Raess PW; van de Geijn GJ; Njo TL; Klop B; Sukhachev D; Wertheim G; McAleer T; Master SR; Bagg A
Am J Hematol; 2014 Apr; 89(4):369-74. PubMed ID: 24276948
[TBL] [Abstract][Full Text] [Related]
2. Possibility of myelodysplastic syndromes screening using a complete blood automated cell count.
Rocco V; Maconi M; Gioia M; Silvestri MG; Tanca D; Catalano T; Avino D; Di Palma A; Rovetti A; Danise P
Leuk Res; 2011 Dec; 35(12):1623-7. PubMed ID: 21764450
[TBL] [Abstract][Full Text] [Related]
3. Beyond the routine CBC: machine learning and statistical analyses identify research CBC parameter associations with myelodysplastic syndromes and specific underlying pathogenic variants.
Pozdnyakova O; Niculescu RS; Kroll T; Golemme L; Raymond N; Briggs D; Kim A
J Clin Pathol; 2023 Sep; 76(9):624-631. PubMed ID: 35577566
[TBL] [Abstract][Full Text] [Related]
4. Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model.
Oster HS; Carmi G; Kolomansky A; Joffe E; Kaye I; Kirgner I; Greenbaum U; Comaneshter D; Mittelman M
Leuk Lymphoma; 2018 Sep; 59(9):2227-2232. PubMed ID: 29295649
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
6. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes.
Saigo K; Takenokuchi M; Imai J; Numata K; Isono S; Zenibayashi M; Tanioka H; Yoshioka T; Nishizawa A; Takada M; Nomura T; Kubota Y
Lab Hematol; 2009; 15(2):13-6. PubMed ID: 19561008
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Int J Hematol; 1993 Aug; 58(1-2):53-61. PubMed ID: 8219112
[TBL] [Abstract][Full Text] [Related]
9. Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory.
Zhu J; Lemaire P; Mathis S; Ronez E; Clauser S; Jondeau K; Fenaux P; Adès L; Bardet V
BMC Cancer; 2022 Sep; 22(1):972. PubMed ID: 36088307
[TBL] [Abstract][Full Text] [Related]
10. Complete blood count and cell population data parameters from the Abbott Alinity hq analyzer are useful in differentiating myelodysplastic syndromes from other forms of cytopenia.
Hwang SM; Nam Y
Int J Lab Hematol; 2022 Jun; 44(3):468-476. PubMed ID: 34877795
[TBL] [Abstract][Full Text] [Related]
11. Discriminating myelodysplastic syndrome and other myeloid malignancies from non-clonal disorders by multiparametric analysis of automated cell data.
Kim SY; Park Y; Kim H; Kim J; Kwon GC; Koo SH
Clin Chim Acta; 2018 May; 480():56-64. PubMed ID: 29378171
[TBL] [Abstract][Full Text] [Related]
12. A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.
Boutault R; Peterlin P; Boubaya M; Sockel K; Chevallier P; Garnier A; Guillaume T; Le Bourgeois A; Debord C; Godon C; Le Bris Y; Theisen O; Kroschinsky F; Moreau P; Béné MC; Platzbecker U; Eveillard M
Br J Haematol; 2018 Dec; 183(5):736-746. PubMed ID: 30406952
[TBL] [Abstract][Full Text] [Related]
13. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.
Martín M; de Paz R; Jiménez-Yuste V; Fernández Bello I; García Arias Salgado E; Alvarez MT; Butta NV
Thromb Haemost; 2013 May; 109(5):909-19. PubMed ID: 23407717
[TBL] [Abstract][Full Text] [Related]
14. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution.
Balduini CL; Guarnone R; Pecci A; Centenara E; Invernizzi R; Ascari E
Haematologica; 1999 Jan; 84(1):12-6. PubMed ID: 10091387
[TBL] [Abstract][Full Text] [Related]
15. A model for automated screening of thalassemia in hematology (math study).
Kneifati-Hayek J; Fleischman W; Bernstein LH; Riccioli A; Bellevue R
Lab Hematol; 2007; 13(4):119-23. PubMed ID: 18192142
[TBL] [Abstract][Full Text] [Related]
16. Platelet mass has prognostic value in patients with myelodysplastic syndromes.
Bowles KM; Warner BA; Baglin TP
Br J Haematol; 2006 Oct; 135(2):198-200. PubMed ID: 16939490
[TBL] [Abstract][Full Text] [Related]
17. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
18. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.
Font P; Loscertales J; Benavente C; Bermejo A; Callejas M; Garcia-Alonso L; Garcia-Marcilla A; Gil S; Lopez-Rubio M; Martin E; Muñoz C; Ricard P; Soto C; Balsalobre P; Villegas A
Ann Hematol; 2013 Jan; 92(1):19-24. PubMed ID: 22948274
[TBL] [Abstract][Full Text] [Related]
19. "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows".
Tsagarakis NJ; Paterakis G; Papadhimitriou SI; Kritikou-Griva E; Goumakou E; Oudatzis G; Theodorakos I; Vasileiou P
Int J Lab Hematol; 2019 Aug; 41(4):542-549. PubMed ID: 31102331
[TBL] [Abstract][Full Text] [Related]
20. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
